ES2266197T3 - Procedimiento in vintro para la introduccion de acido nucleico en una celula (transfeccion) por medio de fosfato de calcio. - Google Patents

Procedimiento in vintro para la introduccion de acido nucleico en una celula (transfeccion) por medio de fosfato de calcio. Download PDF

Info

Publication number: ES2266197T3
Authority: ES; Spain
Prior art keywords: cell; cells; dna; nucleic acid; transfection
Prior art date: 2000-05-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

ES01931696T

Other languages

English (en)

Spanish (es)

Inventor

Markus Horer

Bernd Rehberger

Ulrich Moebius

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Medigene AG

Original Assignee

Medigene AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-05-17

Filing date

2001-05-15

Publication date

2007-03-01

2001-05-15 Application filed by Medigene AG filed Critical Medigene AG

2007-03-01 Application granted granted Critical

2007-03-01 Publication of ES2266197T3 publication Critical patent/ES2266197T3/es

2021-05-15 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims abstract description 76
102000039446 nucleic acids Human genes 0.000 title claims abstract description 60
108020004707 nucleic acids Proteins 0.000 title claims abstract description 60
150000007523 nucleic acids Chemical class 0.000 title claims abstract description 60
239000001506 calcium phosphate Substances 0.000 title claims abstract description 11
229910000389 calcium phosphate Inorganic materials 0.000 title claims abstract description 11
235000011010 calcium phosphates Nutrition 0.000 title claims abstract description 11
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 title claims abstract description 11
238000001890 transfection Methods 0.000 title description 72
238000004519 manufacturing process Methods 0.000 claims abstract description 10
210000004027 cell Anatomy 0.000 claims description 186
108020004414 DNA Proteins 0.000 claims description 86
239000013612 plasmid Substances 0.000 claims description 38
238000011534 incubation Methods 0.000 claims description 19
238000006243 chemical reaction Methods 0.000 claims description 11
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 10
239000002244 precipitate Substances 0.000 claims description 10
238000000338 in vitro Methods 0.000 claims description 9
230000032823 cell division Effects 0.000 claims description 8
239000011575 calcium Substances 0.000 claims description 7
230000008569 process Effects 0.000 claims description 7
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 6
239000002253 acid Substances 0.000 claims description 6
229910052791 calcium Inorganic materials 0.000 claims description 6
210000004962 mammalian cell Anatomy 0.000 claims description 6
230000010076 replication Effects 0.000 claims description 6
239000001569 carbon dioxide Substances 0.000 claims description 5
229910002092 carbon dioxide Inorganic materials 0.000 claims description 5
229910019142 PO4 Inorganic materials 0.000 claims description 4
239000006143 cell culture medium Substances 0.000 claims description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 4
239000010452 phosphate Substances 0.000 claims description 4
150000002500 ions Chemical class 0.000 claims description 3
239000002299 complementary DNA Substances 0.000 claims description 2
210000003527 eukaryotic cell Anatomy 0.000 claims description 2
210000005260 human cell Anatomy 0.000 claims description 2
102000053602 DNA Human genes 0.000 description 80
230000008859 change Effects 0.000 description 45
239000002609 medium Substances 0.000 description 39
238000002309 gasification Methods 0.000 description 25
230000001404 mediated effect Effects 0.000 description 19
239000000203 mixture Substances 0.000 description 19
108090000623 proteins and genes Proteins 0.000 description 16
229920002307 Dextran Polymers 0.000 description 15
238000004113 cell culture Methods 0.000 description 12
239000013598 vector Substances 0.000 description 12
239000000243 solution Substances 0.000 description 11
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 10
239000002245 particle Substances 0.000 description 9
241000894006 Bacteria Species 0.000 description 8
108060001084 Luciferase Proteins 0.000 description 8
230000012010 growth Effects 0.000 description 7
239000001963 growth medium Substances 0.000 description 7
102000004169 proteins and genes Human genes 0.000 description 7
210000001938 protoplast Anatomy 0.000 description 7
230000009261 transgenic effect Effects 0.000 description 7
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
239000005089 Luciferase Substances 0.000 description 6
241000700605 Viruses Species 0.000 description 6
239000001110 calcium chloride Substances 0.000 description 6
235000011148 calcium chloride Nutrition 0.000 description 6
229910001628 calcium chloride Inorganic materials 0.000 description 6
238000004520 electroporation Methods 0.000 description 6
108010030074 endodeoxyribonuclease MluI Proteins 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
239000012634 fragment Substances 0.000 description 6
230000014509 gene expression Effects 0.000 description 6
235000015097 nutrients Nutrition 0.000 description 6
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 5
229930182816 L-glutamine Natural products 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
230000004927 fusion Effects 0.000 description 5
239000002502 liposome Substances 0.000 description 5
238000003153 stable transfection Methods 0.000 description 5
230000001052 transient effect Effects 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
238000010521 absorption reaction Methods 0.000 description 4
210000004748 cultured cell Anatomy 0.000 description 4
238000004806 packaging method and process Methods 0.000 description 4
241000701161 unidentified adenovirus Species 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
229930182566 Gentamicin Natural products 0.000 description 3
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 3
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 3
239000002202 Polyethylene glycol Substances 0.000 description 3
102000004142 Trypsin Human genes 0.000 description 3
108090000631 Trypsin Proteins 0.000 description 3
230000001464 adherent effect Effects 0.000 description 3
238000013142 basic testing Methods 0.000 description 3
210000003855 cell nucleus Anatomy 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
230000012202 endocytosis Effects 0.000 description 3
229960002518 gentamicin Drugs 0.000 description 3
239000006166 lysate Substances 0.000 description 3
239000012139 lysis buffer Substances 0.000 description 3
238000005259 measurement Methods 0.000 description 3
238000000520 microinjection Methods 0.000 description 3
238000012986 modification Methods 0.000 description 3
230000004048 modification Effects 0.000 description 3
229920001223 polyethylene glycol Polymers 0.000 description 3
229920000642 polymer Polymers 0.000 description 3
239000011148 porous material Substances 0.000 description 3
230000009467 reduction Effects 0.000 description 3
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 3
239000012588 trypsin Substances 0.000 description 3
WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
239000004364 Benzylated hydrocarbon Substances 0.000 description 2
101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
238000013459 approach Methods 0.000 description 2
230000003115 biocidal effect Effects 0.000 description 2
239000000872 buffer Substances 0.000 description 2
230000010261 cell growth Effects 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
229960003677 chloroquine Drugs 0.000 description 2
WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 2
238000010367 cloning Methods 0.000 description 2
210000000805 cytoplasm Anatomy 0.000 description 2
238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
230000008014 freezing Effects 0.000 description 2
238000007710 freezing Methods 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
239000002773 nucleotide Substances 0.000 description 2
125000003729 nucleotide group Chemical group 0.000 description 2
238000003752 polymerase chain reaction Methods 0.000 description 2
108091008146 restriction endonucleases Proteins 0.000 description 2
230000035939 shock Effects 0.000 description 2
239000011734 sodium Substances 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000002689 soil Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000010257 thawing Methods 0.000 description 2
238000003151 transfection method Methods 0.000 description 2
230000010474 transient expression Effects 0.000 description 2
238000003146 transient transfection Methods 0.000 description 2
241000972773 Aulopiformes Species 0.000 description 1
108020004638 Circular DNA Proteins 0.000 description 1
241000252203 Clupea harengus Species 0.000 description 1
241000702421 Dependoparvovirus Species 0.000 description 1
241000991587 Enterovirus C Species 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
229920000209 Hexadimethrine bromide Polymers 0.000 description 1
241001135569 Human adenovirus 5 Species 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
108090000604 Hydrolases Proteins 0.000 description 1
102000004157 Hydrolases Human genes 0.000 description 1
102000016943 Muramidase Human genes 0.000 description 1
108010014251 Muramidase Proteins 0.000 description 1
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
241001505332 Polyomavirus sp. Species 0.000 description 1
108700005077 Viral Genes Proteins 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000000843 anti-fungal effect Effects 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
239000000823 artificial membrane Substances 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
210000003578 bacterial chromosome Anatomy 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000010307 cell transformation Effects 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
229960005091 chloramphenicol Drugs 0.000 description 1
WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
238000004163 cytometry Methods 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
230000000694 effects Effects 0.000 description 1
230000005684 electric field Effects 0.000 description 1
210000001163 endosome Anatomy 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
239000007789 gas Substances 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
235000019514 herring Nutrition 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
229910052588 hydroxylapatite Inorganic materials 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000013101 initial test Methods 0.000 description 1
230000010354 integration Effects 0.000 description 1
229960000318 kanamycin Drugs 0.000 description 1
229930027917 kanamycin Natural products 0.000 description 1
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
229930182823 kanamycin A Natural products 0.000 description 1
238000009533 lab test Methods 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000004324 lymphatic system Anatomy 0.000 description 1
230000002132 lysosomal effect Effects 0.000 description 1
238000013411 master cell bank Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
238000002941 microtiter virus yield reduction assay Methods 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
238000005457 optimization Methods 0.000 description 1
238000007500 overflow downdraw method Methods 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
238000012856 packing Methods 0.000 description 1
XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
239000004417 polycarbonate Substances 0.000 description 1
229920000515 polycarbonate Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
239000000047 product Substances 0.000 description 1
230000005855 radiation Effects 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
230000008521 reorganization Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
235000019515 salmon Nutrition 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 description 1
210000001082 somatic cell Anatomy 0.000 description 1
238000004114 suspension culture Methods 0.000 description 1
238000012360 testing method Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
210000003956 transport vesicle Anatomy 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

Landscapes

Genetics & Genomics (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Wood Science & Technology (AREA)
Organic Chemistry (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Biophysics (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Saccharide Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

ES01931696T 2000-05-17 2001-05-15 Procedimiento in vintro para la introduccion de acido nucleico en una celula (transfeccion) por medio de fosfato de calcio. Expired - Lifetime ES2266197T3 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE10024334		2000-05-17
DE10024334A DE10024334B4 (de)	2000-05-17	2000-05-17	Verfahren zum Einbringen von Nukleinsäure in eine Zelle (Transfektion) mittels Calciumphosphat

Publications (1)

Publication Number	Publication Date
ES2266197T3 true ES2266197T3 (es)	2007-03-01

Family

ID=7642499

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES01931696T Expired - Lifetime ES2266197T3 (es)	2000-05-17	2001-05-15	Procedimiento in vintro para la introduccion de acido nucleico en una celula (transfeccion) por medio de fosfato de calcio.

Country Status (8)

Country	Link
US (1)	US20040053410A1 (de)
EP (1)	EP1294919B1 (de)
AT (1)	ATE333508T1 (de)
AU (1)	AU2001258400A1 (de)
CA (1)	CA2409701A1 (de)
DE (2)	DE10024334B4 (de)
ES (1)	ES2266197T3 (de)
WO (1)	WO2001088171A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3621734A4 (de) *	2017-05-09	2020-12-30	Ultragenyx Pharmaceutical Inc.	Skalierbares verfahren zur herstellung von transfektionsreagenzien

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR100492292B1 (ko) *	2002-11-11	2005-05-27	오덕재	유전자의 세포내 도입을 위한 인산칼슘/핵산 복합체의 제조방법
EP2012122A1 (de) *	2007-07-06	2009-01-07	Medigene AG	Strukturproteine von mutierten Parvoviren als Impfstoffe
ES2602610T3 (es)	2007-05-31	2017-02-21	Medigene Ag	Proteína estructural mutada de un parvovirus
ES2742180T3 (es)	2009-03-04	2020-02-13	Deutsches Krebsforsch	Proteína activadora del ensamblaje (AAP) y su uso para la fabricación de partículas de parvovirus que consisten esencialmente en VP3
AR082925A1 (es)	2010-09-08	2013-01-16	Medigene Ag	Proteinas estructurales mutadas por parvovirus con epitopo de celulas b de proteccion cruzada, producto y metodos relacionados

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1993004169A1 (en) *	1991-08-20	1993-03-04	Genpharm International, Inc.	Gene targeting in animal cells using isogenic dna constructs
CA2166278A1 (en) *	1993-06-29	1995-01-12	Denis J. Gospodarowicz	A truncated keratinocyte growth factor (kgf) having increased biological activity
EP0779931B1 (de) *	1994-09-08	2002-11-20	Genentech Inc.	Verfahren zur kalziumphosphat-transfektion
US5976807A (en) *	1998-03-18	1999-11-02	Pharmacopeia, Inc.	Eukaryotic cells stably expressing genes from multiple transfected episomes
US20020006664A1 (en) *	1999-09-17	2002-01-17	Sabatini David M.	Arrayed transfection method and uses related thereto
US7156579B2 (en) *	2004-09-02	2007-01-02	Clemson University	Manufactured caverns in carbonate rock

2000
- 2000-05-17 DE DE10024334A patent/DE10024334B4/de not_active Expired - Fee Related
2001
- 2001-05-15 AT AT01931696T patent/ATE333508T1/de not_active IP Right Cessation
- 2001-05-15 AU AU2001258400A patent/AU2001258400A1/en not_active Abandoned
- 2001-05-15 WO PCT/EP2001/005531 patent/WO2001088171A1/de not_active Ceased
- 2001-05-15 DE DE50110507T patent/DE50110507D1/de not_active Expired - Lifetime
- 2001-05-15 EP EP01931696A patent/EP1294919B1/de not_active Expired - Lifetime
- 2001-05-15 US US10/276,207 patent/US20040053410A1/en not_active Abandoned
- 2001-05-15 ES ES01931696T patent/ES2266197T3/es not_active Expired - Lifetime
- 2001-05-15 CA CA002409701A patent/CA2409701A1/en not_active Abandoned

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3621734A4 (de) *	2017-05-09	2020-12-30	Ultragenyx Pharmaceutical Inc.	Skalierbares verfahren zur herstellung von transfektionsreagenzien
US12487152B2 (en)	2017-05-09	2025-12-02	Ultragenyx Pharmaceutical Inc.	Scalable method for producing transfection reagents

Also Published As

Publication number	Publication date
DE10024334B4 (de)	2006-06-01
CA2409701A1 (en)	2001-11-22
DE50110507D1 (de)	2006-08-31
DE10024334A1 (de)	2001-12-06
EP1294919A1 (de)	2003-03-26
AU2001258400A1 (en)	2001-11-26
US20040053410A1 (en)	2004-03-18
EP1294919B1 (de)	2006-07-19
WO2001088171A1 (de)	2001-11-22
ATE333508T1 (de)	2006-08-15

Publication	Publication Date	Title
ES2962509T3 (es)	2024-03-19	Métodos y composiciones para modificar ADN genómico
WO1987006614A1 (en)	1987-11-05	Electric field mediated dna transformation of plant cells and organelles
US20200370035A1 (en)	2020-11-26	Methods for in vitro site-directed mutagenesis using gene editing technologies
WO2019090175A1 (en)	2019-05-09	Novel crispr-associated transposon systems and components
Frengen et al.	2000	Modular bacterial artificial chromosome vectors for transfer of large inserts into mammalian cells
Itoh et al.	1977	Involvement of DNA gyrase in bacteriophage T7 DNA replication
US11866728B2 (en)	2024-01-09	Engineered retrons and methods of use
ES2266197T3 (es)	2007-03-01	Procedimiento in vintro para la introduccion de acido nucleico en una celula (transfeccion) por medio de fosfato de calcio.
Bost et al.	2023	Application of the endogenous CRISPR-Cas type ID system for genetic engineering in the thermoacidophilic archaeon Sulfolobus acidocaldarius
BR112020015889A2 (pt)	2020-12-15	Processo de fabricação de sistemas fechados para células car-t
US9670505B2 (en)	2017-06-06	Mitochondrial expression vector and method for the transformation of mitochondria
Confraria et al.	2016	Using Arabidopsis protoplasts to study cellular responses to environmental stress
Velmurugan et al.	2003	Stable propagation of ‘selfish’genetic elements
Cohen et al.	2016	Biotechnology: principles and processes
Weber et al.	2022	Precise and Scarless Insertion of Transposable Elements by Cas9-Mediated Genome Engineering
White et al.	1986	Methods to enhance uptake of DNA in polyethylene glycol-mediated transformation
Valiyev	2021	Modified Gibson assembly application on the construction of the recombinant plasmid
CN120966726A (zh)	2025-11-18	一种高抗生素抗性的解淀粉芽孢杆菌基因工程菌及其构建方法和应用
CN121175417A (zh)	2025-12-19	Dna编辑方法和利用了该方法的细胞制造方法、以及用于在这些方法中使用的dna编辑用载体和dna编辑用试剂盒
KR100631488B1 (ko)	2006-10-09	단백질 도입부위 및 막활성화 부위가 함유된 새로운 합성펩타이드 및 이를 이용한 유전자 전달 방법
Mayorova et al.	2023	Overcoming the Protective Barriers of Cells in the Transformation of Bacteria with Exogenous DNA Using the Example of Rhodobacter capsulatus
Sengar et al.	2026	Gene cloning and protein expression systems
Cocito et al.	1977	Inhibition of lytic induction in lysogenic cyanophyces
Flores-Valdez et al.	2021	Construction of Novel Live Genetically Modified BCG Vaccine Candidates Using Recombineering Tools
Barman et al.	2013	Heat shock at 37 C with plasmid ligated at 37 C yields more number of Escherichia coli transformants than plasmid ligated at 16 C a possible role of ligated plasmid conformation during heat shock